AbbVie files Biologics License Application for etentamig in relapsed/refractory multiple myeloma
AbbVie submitted a Biologics License Application to the U.S. FDA for etentamig, a second‑generation BCMA × CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The filing relies on the Phase 3 CERVINO trial, which enrolled 393 patients and showed a 74.0% overall response rate versus 45.7% for standard therapies, and a 60% risk reduction in progression‑free survival. The company highlighted a manageable safety profile, with discontinuations due to adverse events of 3.6% versus 14% for comparators.
Why it matters
If the FDA approves etentamig, AbbVie could add a new product to its multiple‑myeloma portfolio, potentially generating significant future revenue. The filing also signals to investors that the company expects the drug to meet regulatory standards, which may affect the stock’s valuation.
Key facts
- 1AbbVie submitted a Biologics License Application to the FDA on Oct. 27 2026. news.abbvie.com
- 2The Phase 3 CERVINO study randomized 393 patients 1:1 to etentamig or standard available therapies. investing.com
- 3Etentamig achieved an overall response rate of 74.0% versus 45.7% for standard therapies. news.abbvie.com
- 4Progression‑free survival showed a 60% risk reduction versus standard therapies. news.abbvie.com
- 5Discontinuations due to treatment‑emergent adverse events were 3.6% for etentamig versus 14% for standard therapies. stocktitan.net
- 6Among patients receiving a single step‑up dose, cytokine release syndrome occurred in 28.3% of etentamig patients, all grade 1 or 2. stocktitan.net
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.